分子靶向药物联合治疗EGFR-TKIs继发性耐药肺癌的研究进展

Advances of combinations of different molecular targeted drugs in lung cancer secondary resistant to EGFR-TKIs

表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)是晚期非小细胞肺癌EGFR敏感突变患者的一线治疗方案。然而,继发性耐药的出现不可避免。继发性耐药有多种机制,其中以EGFR T790M突变为主要机制之一。目前,靶向药物联合是治疗EGFR-TKIs继发性耐药肺癌的重要策略。该文对其近年研究概况作一综述。

EGFR-TKIs is the first-line treatment of EGFR sensitive mutations in patients with advanced nonsmall cell lung cancer. However,the emergence of acquired drug resistance is inevitable. There are a variety of mechanisms for secondary drug resistance,of which EGFR T790 M mutation is one of the main mechanisms. Currently,combinations of different molecular targeted drugs in the treatment of lung cancer secondary resistant to EGFR-TKIs are the important strategies. Their research progress is reviewed in this paper.